Vor Biopharma financials
$18.33+0.11%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$47.9M | -$35.2M | -$36.0M | -$28.1M | -$274.3M | -$33.3M | -$31.3M | -$28.5M | -$29.0M | -$32.3M | -$28.1M | -$35.3M |
| Net income | -$62.8M | -$219.6M | $1.72B | -$812.7M | -$1.57B | -$32.5M | -$30.7M | -$27.6M | -$27.8M | -$30.8M | -$26.3M | -$33.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.16 | $-5.11 | $84.87 | $-121.63 | $-251.24 | $-5.21 | $-4.55 | $-8.05 | $-8.20 | $-9.00 | $-7.74 | $-9.80 |
| EBITDA | -$47.8M | -$35.1M | -$35.9M | -$28.1M | -$272.2M | -$32.5M | -$30.4M | -$27.7M | -$28.2M | -$31.4M | -$27.2M | -$34.4M |
| Operating cash flow | -$25.4M | -$38.2M | -$22.8M | -$53.7M | -$35.2M | -$31.1M | -$24.1M | -$23.3M | -$21.8M | -$30.5M | -$24.0M | -$27.9M |
| Free cash flow | -$25.5M | -$38.3M | -$23.1M | -$53.9M | -$35.3M | -$31.3M | -$24.1M | -$23.3M | -$21.9M | -$30.6M | -$24.1M | -$28.4M |
| Diluted shares | 54.3M | 43.0M | 20.3M | 6.7M | 6.3M | 6.2M | 6.8M | 3.4M | 3.4M | 3.4M | 3.4M | 3.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $107.9M | $169.9M | $396.5M | $160.5M | $190.6M | $50.0M |
| Short-term investments | $358.3M | $321.7M | $58.7M | $10.0M | $10.0M | $10.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $481.1M | $506.7M | $464.1M | $176.2M | $205.4M | $109.3M |
| Total liabilities | $681.3M | $657.2M | $628.4M | $2.40B | $1.71B | $43.2M |
| Shareholders' equity | -$200.2M | -$150.4M | -$164.3M | -$2.23B | -$1.51B | $66.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology